Fierce Pharma August 26, 2024
Even as Johnson & Johnson prepares to weather the impact of negotiated Medicare drug prices on two of its top medicines, the company is aiming to change a different government pricing framework with a new policy for hospital payments under the 340B drug discount program.
Under J&J’s new rebate model, eligible hospitals and healthcare organizations will have to seek rebates on the company’s big-selling Stelara and Xarelto only after purchasing the drugs at commercial prices. Currently, the eligible providers get the 340B discounts at the time of purchase.
The drugmaker outlined the policy in a notice issued on Aug. 23, stipulating that the tweaks would take effect on October 15. Covered entities under the program must submit rebate claims data...
Today's Sponsors
Today's Sponsor